Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

NCT07565155 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

NCT NCT07565155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07565155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency
Lead sponsor
University of Miami
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
January 1, 2032
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

homologous recombination deficiency, pancreatic adenocarcinoma